Receptor.ai

Executive Summary

Receptor.ai is a UK-based AI-driven drug discovery company founded in 2019, specializing in a multiplatform AI ecosystem that designs novel therapeutics across small molecules, peptides, and proximity inducers. The company positions itself as a modality-agnostic partner, helping discovery teams navigate structural uncertainty and complex optimization challenges from hit discovery to lead optimization. With its proprietary AI platform, Receptor.ai aims to accelerate the development of novel therapeutics by leveraging machine learning to predict and optimize molecular properties, thereby reducing the time and cost associated with traditional drug discovery. The company is based in London and operates in the competitive AI drug discovery landscape, targeting both internal programs and external partnerships. Receptor.ai has not disclosed significant funding or valuation details, suggesting it is in an early stage of development. Given its focus on multiple therapeutic modalities and its AI-first approach, the company is well-positioned to capitalize on the growing interest in AI-enabled drug discovery. However, as a private entity with limited public information, its progress and future trajectory remain speculative. Key upcoming catalysts could include securing a Series A funding round, announcing a collaboration with a major pharmaceutical company, or advancing a lead candidate into preclinical development. These milestones would validate its platform and provide clearer signals of its potential impact on the industry.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round70% success
• Q2 2027Pharma Partnership or Collaboration50% success
• Q1 2027Lead Optimization Milestone for Internal Program40% success